Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

Insilico Medicine and ChemDiv form a strategic drug discovery service alliance


Diego (CA) - Insilico Medicine and ChemDiv, Inc. launched a new strategic

collaboration to provide certain pharmaceutical and biotechnology companies

with end-to-end drug discovery solutions. This collaboration combines the most

advanced artificial intelligence (AI) techniques with a

premium integrated drug discovery shared risk platform. The combination of complementary capabilities introduces

a new value for companies working in the field, giving them a powerful tool for

quick, cost-effective therapeutic product development.


pleased to partner with ChemDiv, the leading discovery contract research

organization, which built a massive repository of small molecules,” said Alex

Zhavoronkov, PhD., CEO of Insilico Medicine. “ChemDiv has had a number of

highly successful collaborations with pharmaceutical companies in multiple

therapeutic areas, moving their discoveries from the

unique chemistry idea into the clinic. Together we willimprove the novelty, quality and

efficiency of preclinical drug discovery and bring our technology and

experience to other biotech and pharma partners.”


Bugrov, Executive Director of ChemDiv said: “With Insilico Medicine’s AI

technology, previously intractable targets could  become viable therapeutic opportunities and

the time for preclinical drug discovery could dramatically shorten. Our joint goal is to generate new leads against identified and

predicted novel targets. It

allows us to continuously deliver great service to our partners and help them

develop effective treatments for unmet medical needs.”


commercial terms will include technology access, success focused milestone and




ChemDiv is a recognized global leader in drug

discovery solutions. Over the past 29 years ChemDiv has delivered hundreds of

leads, drug candidates and new drugs in the area of CNS, oncology, virology,

inflammation, cardiometabolic and immunology, to pharma, biotech and academic

partners around the globe. [www.chemdiv.com]


Insilico Medicine

Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with offices in six countries and regions. The Company was the first to apply the generative adversarial networks (GANs) and reinforcement learning (RL) to generate new molecular structures with the specified parameters in 2015. In addition to collaborating with large pharmaceutical companies, Insilico Medicine is also pursuing internal drug discovery programs in different disease areas and anti-aging fields. Recently, Insilico Medicine published some of the resuts in Nature Biotechnology, and secured $37 million in series B funding. Website http://insilico.com/

Media Contacts

For further information, images or interviews, please contact:

Insilico Medicine:

Klug Gehilfe, ai@pharma.ai

ChemDiv Inc.: Ron Demuth, rdemuth@chemdiv.com

0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies